GlassScriptPhysician profile
Stephanie L Bayers
NPI 1346668902
$6,490.35
in general payments reported to CMS, 2019-2025
37 companies · $499 in 2025
The $499 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,057 · 2020: $1,162 · 2021: $416 · 2022: $1,140 · 2023: $641 · 2024: $575 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.10 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.25 | 2019-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $603.52 | 2019-2024 | Absorica Ld, Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $590.99 | 2019-2024 | Aklief, Twyneo, Oracea |
| Lilly USA, LLC | $406.98 | 2019-2024 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $388.05 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $364.55 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $358.59 | 2019-2024 | Dupixent |
| Genzyme Corporation | $349.69 | 2019-2024 | |
| Prugen, INC. Pharmaceuticals | $328.59 | 2019 | |
| Janssen Biotech, INC. | $275.78 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $196.22 | 2019-2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $191.79 | 2019-2021 | |
| Celgene Corporation | $157.81 | 2019 | |
| Incyte Corporation | $144.68 | 2021-2024 | Opzelura |
| Ucb, INC. | $144.12 | 2021-2025 | Bimzelx |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $140.89 | 2019-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.97 | 2019-2021 | |
| Revance Therapeutics, INC. | $91.75 | 2025 | Daxxify |
| Encore Dermatology INC. | $53.44 | 2019 | |
| Epi Health, LLC | $53.40 | 2020-2022 | |
| Almirall LLC | $52.78 | 2021 | |
| Dermavant Sciences, INC. | $51.71 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $49.56 | 2020 | |
| Dermira, INC. | $48.23 | 2019-2020 | |
| Misonix INC | $47.71 | 2019 | |
| Smith+Nephew, INC. | $44.44 | 2019-2025 | Grafix |
| E.R. Squibb & Sons, L.L.C. | $37.01 | 2022-2023 | Sotyktu |
| Glenmark Therapeutics INC. | $32.00 | 2019 | |
| Mission Pharmacal Company | $24.70 | 2019 | |
| Stemline Therapeutics INC. | $23.66 | 2020 | |
| Mentor Worldwide LLC | $22.47 | 2019 | |
| Mylan Pharmaceuticals INC. | $18.91 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.39 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.92 | 2024 | Zoryve |
| Nabriva Therapeutics, Plc | $14.29 | 2021 | |
| Journey Medical Corporation | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Bayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.